Immunocore Holdings PLC

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Neoadjuvant Tebentafusp for Uveal Melanoma

Study of IMC-P115C in Advanced PRAME-Positive Cancers

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Adjuvant Tebentafusp in High Risk Ocular Melanoma